Compare · ABBV vs HYPD
ABBV vs HYPD
Side-by-side comparison of AbbVie Inc. (ABBV) and Hyperion DeFi Inc. (HYPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and HYPD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 10826.1x HYPD ($41.5M).
- Over the past year, ABBV is up 34.5% and HYPD is down 78.5% - ABBV leads by 113.0 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 9 for HYPD).
- ABBV has more recent analyst coverage (25 ratings vs 2 for HYPD).
- Company
- AbbVie Inc.
- Hyperion DeFi Inc.
- Price
- $254.52+0.06%
- $2.76-1.08%
- Market cap
- $449.63B
- $41.5M
- 1M return
- +14.38%
- -14.15%
- 1Y return
- +34.48%
- -78.48%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2018
- News (4w)
- 23
- 9
- Recent ratings
- 25
- 2
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest HYPD
- Hyperion DeFi Enters Agreement with Skew Technologies to Launch HIP-3 Perpetual Futures Market and Listing Service
- Hyperion DeFi Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Walters Happy David was granted 58,917 shares, increasing direct ownership by 53% to 170,847 units (SEC Form 4)
- Director Strahlman Ellen R was granted 58,917 shares, increasing direct ownership by 65% to 150,078 units (SEC Form 4)
- Director Jacobson Rachel was granted 58,917 shares, increasing direct ownership by 105% to 115,218 units (SEC Form 4)
- Director Geltzeiler Michael S was granted 58,917 shares, increasing direct ownership by 67% to 146,932 units (SEC Form 4)
- Hyperion DeFi Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Hyperion DeFi Inc.
- Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
- Hyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets